510(k) Report

FDA applicant

I-Sens, Inc.

Seoul, KR28 decisions2008–20260 recalls

FDA records 28 decisions for I-Sens, Inc. (Seoul, KR) from 2008 to 2026: 28 510(k) clearances. Most are in product codes NBW (System, Test, Blood Glucose, Over The Counter) and CGA (Glucose Oxidase, Glucose). Since 2016 its 510(k)s took a median of 171 days from receipt to decision, against 190 for FDA’s reviews in the same codes and years. Its devices cite 22 predicates, 17 of them its own earlier devices. No recall is linked to its devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, clinical chemistry panel, where it files most

How often FDA has decided I-Sens, Inc.’s devices, and how often a recall has named them.

FDA decisions per year

1in 2023

2008: 12009: 12010: 12011: 22012: 42013: 42015: 12016: 12017: 22018: 32019: 12020: 32021: 12022: 12023: 12026 (partial year): 1
2008high 4 (2012) · low 0 (2014)2026

2026 so far, outlined.

Recalls per year

No recall linked to its devices since 2008.

FIG. 1 — I-Sens, Inc. by year, 2008–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like I-Sens, Inc.’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report